A Study to Evaluate the Safety and Efficacy of Obinutuzumab Compared With Placebo in Participants With Lupus Nephritis (LN)

Exclusion Criteria

• •Retinitis, poorly controlled seizure disorder, acute confusional state, myelitis, stroke or stroke syndrome, cerebellar ataxia, or dementia that is currently active and resulting from SLE
• •Presence of rapidly progressive glomerulonephritis
• •Severe renal impairment as defined by estimated Glomerular Filtration Rate (GFR) \<30 milliliters per minute (mL/min) or the need for dialysis or renal transplant
• •Greater than 50% of glomeruli with sclerosis on renal biopsy
• •Treatment with cyclophosphamide or calcineurin inhibitors within the 3 months prior to randomization
• •Unstable disease with thrombocytopenia or at high risk for developing clinically significant bleeding or organ dysfunction requiring therapies such as plasmapheresis or acute blood or platelet transfusions
• •History of severe allergic or anaphylactic reactions to monoclonal antibodies or known hypersensitivity to any component of the obinutuzumab infusion
• •Significant or uncontrolled medical disease in any organ system not related to SLE or LN, which, in the investigator's opinion, would preclude participant participation
• •Concomitant chronic conditions, excluding SLE, (e.g., asthma, Crohn's disease) that required oral or systemic steroid use in the 52 weeks prior to screening
• •Previous treatment with an anti-cluster of differentiation (CD20)-targeted therapy within 12 months
• •Previous treatment with a biologic B-cell-targeted therapy (other than anti-CD20) within 6 months of randomization
• •Known intolerance to MMF or MPA